# Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects

> **NCT00368238** · PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 96 (—)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Recombinant human erythropoietin alfa (drug)
- **DRUG:** Aspirin (drug)
- **DRUG:** Clopidogrel (drug)

## Key facts

- **NCT ID:** NCT00368238
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** —
- **Final completion:** 2006-07
- **Target enrollment:** 96 (—)
- **Last updated:** 2006-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00368238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00368238, "Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00368238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*